MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Epidermal growth factor receptor (EGFR) targeted therapies show limited efficacy in head and neck squamous cell carcinoma (HNSCC).
• Acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) like erlotinib is a significant therapeutic challenge in HNSCC.
• Understanding the molecular mechanisms of erlotinib resistance is crucial for developing effective treatment strategies.

Purpose of the Study:

• To investigate the molecular mechanisms underlying acquired resistance to erlotinib in HNSCC.
• To identify genetic and proteomic alterations associated with erlotinib resistance.
• To evaluate the therapeutic potential of targeting identified pathways in resistant HNSCC.

Main Methods:

• Integrated multi-omics approach including whole exome sequencing, quantitative proteomic, and phosphoproteomic profiling.
• Analysis of erlotinib-resistant HNSCC cell lines (SCC-R).
• Genomic, proteomic, and phosphoproteomic data integration to identify key molecular alterations.

Main Results:

• Observed gene amplification of AXL kinase and transcription factor YAP1, leading to protein overexpression in resistant cells.
• Identified constitutively active mutant MAP2K1 (p.K57E) in erlotinib-resistant SCC-R cells.
• Revealed alterations in the MAPK pathway and its downstream targets through integrated multi-omics analysis.

Conclusions:

• Multiple genetic, proteomic, and phosphoproteomic alterations contribute to erlotinib resistance in HNSCC.
• Erlotinib-resistant HNSCC cells remain sensitive to MAPK pathway inhibition.
• Targeting the MAPK pathway represents a viable therapeutic strategy for erlotinib-resistant HNSCC.